Clinical Trial Update: Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine [Phase 3]

View source ↗

Summary

A Phase 3 study sponsored by Abbott evaluated the safety of Depakote ER (divalproex sodium) for migraine prevention in adolescents; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• DEPAKOTE ER (DIVALPROEX SODIUM)

Snippet

Sponsor: Abbott | Conditions: Migraine | Phase 3 | Status: COMPLETED